comparemela.com

Page 5 - Abionyx News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ABIONYX Pharma: ABIONYX Announces Positive Clinical Findings for CER-001 in Treating COVID-19, Published in Biomedecines, Demonstrating That CER-001 Limits Inflammation Effects

Improvement of reverse cholesterol transport Reduction of inflammatory markers and cytokines A treatment option for patients with COVID-19 Regulatory News: ABIONYX Pharma (FR0012616852

France generalLouis victor delouvrierNicolas merigeauDensity lipoprotein particles administrationMulti omics exploriatory investigationAnnual resultsVictor delouvrier

ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company s Share Capital

Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority) Regulatory News: ABIONYX Pharma (Paris:ABNX): Market:

Arthur rouillLouis victor delouvrierFrench financial markets authorityFrench commercialGeneral regulationsEuronext parisVictor delouvrier

ABIONYX Pharma Provides an Update on Its Business and Cash Position for Q4 2021

Consolidated revenue in 2021 including the firstmonth of activity from IRIS Pharma: €675K Cash position of €7.9 million as of December 31, 2021 Continued repositioning of natural bio-HDL

Arthur rouillLouis victor delouvrierUniversity of bariCompassionate access authorizationAnnual resultsVictor delouvrier

ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company s Share Capital

Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority) Regulatory News: ABIONYX Pharma (Paris:ABNX): Market:

Arthur rouillLouis victor delouvrierFrench financial markets authorityFrench commercialGeneral regulationsEuronext parisVictor delouvrier

ABIONYX Pharma Announces That the French Drug Safety Agency (Agence Nationale de Sécurité du Médicament or ANSM) Has Granted a Compassionate Access Authorization for the bio-HDL (CER-001) in COVID-19 Disease

Regulatory News: ABIONYX Pharma (FR0012616852 ABNX PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today announces

Arthur rouillLouis victor delouvrierFrench drug safety agency agence nationale deRegulatory newsFrench drug safety agencyAgence nationaleCompassionate access authorizationTemporary authorizationsCompassionate access authorizationsVictor delouvrierS 233 curitM 233 dicament

vimarsana © 2020. All Rights Reserved.